Rutgers Office for Research is proud to announce the four Rutgers students who will be the inaugural recipients of its Nokia Bell Labs Scholarship.
Rutgers, The State University of New Jersey, improved its standing in the National Academy of Inventors (NAI) Universities Granted Utility Patents rankings, moving up five spots to come in 68th in the world and 43rd among U.S. institutions in this year鈥檚 list.
NanoNewron, Inc., a startup founded based on technology developed at Rutgers, The State University of New Jersey, looks to advance its potentially game changing approach towards treating Alzheimer鈥檚 Disease and other neurological conditions.
A startup company formed based on technology developed at Rutgers, The State University of New Jersey, seeks to use artificial intelligence and automation to help researchers advance their work and make breakthrough discoveries.
Enver Cagri Izgu, PhD, from the School of Arts and Sciences at Rutgers-New Brunswick, and his team will use a nearly $2 million NIH grant to develop diverse molecules with 鈥減rogrammed functionality鈥� to address the fundamental challenges in therapeutic approaches that rely on modulating gene expression.
Rutgers startup Zena Therapeutics strives to create narcotic medications that will minimize or even eliminate overdoses from prescription drugs. Co-founded by Eileen Carry, PhD, and Ariane Vasilatis, PhD, the company is based on an innovation developed at Rutgers, The State University of New Jersey: a novel compound that does not increase the risk of overdose if taken with other central nervous system depressing substances such as opioids and alcohol.
A catalyst that converts waste CO鈧� to chemical products. A monoclonal antibody that could revolutionize the detection of tuberculosis. Both innovations were developed at Rutgers, The State University of New Jersey, and both received 2024 Edison Patent Awards at the annual Research & Development (R&D) Council of New Jersey (RDNJ) banquet.
Rutgers, The State University of New Jersey, has released its聽Rutgers Research and Innovation Annual Impact Report for Fiscal Year 2024.
Base editing technology invented at Rutgers, The State University of New Jersey, and exclusively licensed to Revvity, Inc. subsidiary Horizon Discovery, has been sub-licensed to biopharmaceutical company AstraZeneca to support its creation of cell therapies for the treatment of cancer and immune-mediated diseases.
Rutgers is part of a new federally funded regional collaboration to drive economic and technological advancements in photonics, the National Science Foundation (NSF) announced. The consortium, which includes researchers from Rutgers-Newark and Rutgers-New Brunswick, awarded a development grant from the NSF鈥檚 Regional Innovation Economic Engine consortium, led by Princeton University and co-led by Rowan University, with partners throughout New Jersey and neighboring states Delaware, Pennsylvania and New York.
In an effort to expand and enhance New Jersey鈥檚 research and innovation ecosystem, Rutgers Office for Research鈥檚 Innovation Ventures will participate in a technology transfer partnership with the New Jersey Association of State Colleges and Universities (NJASCU).
Rutgers, The State University of New Jersey, has earned prestigious accreditation from the Association for the Accreditation of Human Research Protection Programs (AAHRPP) for the first time. Through this coveted certification, Rutgers Human Research Protection Program (HRPP) and Institutional Review Board (IRB) join the elite ranks of University Human Research Protection programs.
As the United States and the world continue to battle COVID-19 and other zoonotic diseases, a group of scientists and experts from New Jersey, Delaware, Pennsylvania, Maryland, West Virginia and Virginia will convene for a Regional One Health Consortium Conference at Rutgers University. Participants will consist of scientists who will share data and expertise on how to address a variety of topics and diseases affecting the health of humans, animals and the environment across the region, including ticks and tick-borne diseases, mosquitoes, rabies, and bird flu.
Rutgers researcher, Grace Brannigan, has co-authored a study published in The Proceedings of the National Academy of Sciences (PNAS) that centers around the connection between gene mutations in protein sequences and diseases.
A Rutgers researcher will use genomics, genetics, and cell biology to identify and understand the corals鈥� response to heat stress conditions and to pinpoint master regulatory genes involved in coral bleaching due to global warming and climate change. The researcher and his team will use a novel gene-editing tool as a resource to knock down some gene functions with the goal of boosting the corals鈥� abilities to survive.
The Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB), headquartered at the Rutgers Institute for Quantitative Biomedicine, announces the expansion of its data storage capacity through the Amazon Web Services (AWS) Open Data Sponsorship Program. The AWS program is providing the RCSB PDB with more than 100 terabytes of storage for no-cost delivery of Protein Data Bank information to millions of scientists, educators, and students around the world working in fundamental biology, biomedicine, bioenergy, and bioengineering/biotechnology.
A pair of Rutgers researchers are teaming up to combat climate change and worldwide hunger at the same time. Yong Mao, associate research professor and lead biologist in the Laboratory for Biomaterials Science at Rutgers School of Arts and Sciences, and Joseph Freeman, professor, director of the Musculoskeletal Regeneration Laboratory, and graduate program director of biomedical engineering in Rutgers School of Engineering, will collaborate with Atelier Meats, a biotechnology company, to develop and produce lab-grown, structured meats.
In a landmark genetic study of more than 121,000 people, an international consortium called SCHizophrenia Exome Meta-Analysis (SCHEMA), led by researchers at the Broad Institute of MIT and Harvard, has identified extremely rare protein-disrupting mutations in 10 genes that strongly increase an individual's risk of developing schizophrenia. The Genomic Psychiatry Cohort (GPC) study, based at Rutgers, The State University of New Jersey and led by Drs. Carlos and Michele Pato, is a major contributor to this study and the second, complementary study, led by researchers at Cardiff University on behalf of the Psychiatric Genomics Consortium (PGC).
A Rutgers researcher鈥檚 new formula with Investigational New Drug (IND) status has successfully alleviated a patient鈥檚 long-term severe gastrointestinal (GI) illness associated with post-acute COVID-19 syndrome, or long-haul COVID, in a recent study. The study鈥檚 results on the formula developed by Liping Zhao, Ph.D., are now published in an article titled 鈥淣utritional Modulation of Gut Microbiota Alleviates Severe Gastrointestinal Symptoms in a Patient with Post-Acute COVID-19 Syndrome鈥� in mBio, a peer-reviewed journal of the American Society for Microbiology.
The Center for Tobacco Studies at Rutgers, The State University of New Jersey received a $2.6 million grant from the National Cancer Institute (NCI) to evaluate cigarette relighting 鈥� the practice of smoking a cigarette, extinguishing it, and lighting it again to smoke 鈥� as well as its consequences on health and efforts to quit smoking.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right